Dalmelitinib Mesylate

甲磺酸达麦利替尼

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameDalmelitinib Mesylate
Drug Alias NameHS-10241HS10241
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co Ltd
Inactive CompaniesAtridia Pty Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsCarcinomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A